GT Biopharma, Inc.
GTBP
$0.43
-$0.01-1.22%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -115.42% | 26.33% | 17.25% | -21.13% | -73.25% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2,970.18% | -402.69% | -12,955.56% | 86.03% | 81.49% |
| Change in Net Operating Assets | -211.11% | -2,653.85% | 142.94% | 66.28% | -54.63% |
| Cash from Operations | -0.08% | 8.99% | 11.01% | -8.25% | -45.77% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -99.99% | -100.00% | -21.52% | 741.76% |
| Cash from Investing | -- | -99.99% | -100.00% | -21.52% | 741.76% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 84.68% | -64.65% | -64.65% | -- | -52.52% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 430.07% | 151.01% | 118.18% | -- | -52.52% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.51% | -200.70% | -160.60% | 634.74% | 164.55% |